HomeCompareEGRX vs KMB

EGRX vs KMB: Dividend Comparison 2026

EGRX yields 586.51% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EGRX wins by $215504.58M in total portfolio value
10 years
EGRX
EGRX
● Live price
586.51%
Share price
$0.34
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$215504.63M
Annual income
$161,378,417,110.69
Full EGRX calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — EGRX vs KMB

📍 EGRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEGRXKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EGRX + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EGRX pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EGRX
Annual income on $10K today (after 15% tax)
$49,853.37/yr
After 10yr DRIP, annual income (after tax)
$137,171,654,544.09/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, EGRX beats the other by $137,171,650,114.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EGRX + KMB for your $10,000?

EGRX: 50%KMB: 50%
100% KMB50/50100% EGRX
Portfolio after 10yr
$107752.34M
Annual income
$80,689,211,161.01/yr
Blended yield
74.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

EGRX
Analyst Ratings
2
Buy
3
Hold
1
Sell
Consensus: Hold
Altman Z
1.7
Piotroski
4/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EGRX buys
0
KMB buys
0
No recent congressional trades found for EGRX or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEGRXKMB
Forward yield586.51%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$215504.63M$45.9K
Annual income after 10y$161,378,417,110.69$5,211.33
Total dividends collected$210965.27M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold

Year-by-year: EGRX vs KMB ($10,000, DRIP)

YearEGRX PortfolioEGRX Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$69,351$58,651.03$11,314$613.68+$58.0KEGRX
2$454,347$380,141.02$12,865$759.19+$441.5KEGRX
3$2,813,681$2,327,530.38$14,709$943.96+$2.80MEGRX
4$16,481,619$13,470,979.69$16,919$1,180.17+$16.46MEGRX
5$91,381,654$73,746,322.23$19,588$1,484.33+$91.36MEGRX
6$479,912,426$382,134,055.57$22,838$1,879.06+$479.89MEGRX
7$2,389,083,497$1,875,577,201.52$26,832$2,395.60+$2389.06MEGRX
8$11,282,425,682$8,726,106,340.14$31,788$3,077.63+$11282.39MEGRX
9$50,585,242,215$38,513,046,735.24$38,000$3,986.82+$50585.20MEGRX
10$215,504,626,280$161,378,417,110.69$45,872$5,211.33+$215504.58MEGRX

EGRX vs KMB: Complete Analysis 2026

EGRXStock

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Full EGRX Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this EGRX vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EGRX vs SCHDEGRX vs JEPIEGRX vs OEGRX vs KOEGRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.